1. Comparison of Two Genotyping Methods for Distinguishing Recrudescence from Reinfection in Antimalarial Drug Efficacy/Effectiveness Trials.
- Author
-
Fulakeza JRM, Banda RL, Lipenga TR, Terlouw DJ, Nkhoma SC, and Hodel EM
- Subjects
- Artemether, Lumefantrine Drug Combination therapeutic use, Artemisinins therapeutic use, Child, Cluster Analysis, Drug Combinations, Female, Gene Expression, Genotype, Genotyping Techniques, Humans, Malaria, Falciparum diagnosis, Malaria, Falciparum parasitology, Malawi, Male, Merozoites drug effects, Merozoites growth & development, Plasmodium falciparum genetics, Plasmodium falciparum growth & development, Polymorphism, Single Nucleotide, Quinolines therapeutic use, Recurrence, Treatment Outcome, Antigens, Protozoan genetics, Antimalarials therapeutic use, Malaria, Falciparum drug therapy, Merozoite Surface Protein 1 genetics, Merozoites genetics, Plasmodium falciparum drug effects, Protozoan Proteins genetics
- Abstract
Genotyping of allelic variants of Plasmodium falciparum merozoite surface proteins 1 and 2 ( msp-1 and msp-2 ), and the glutamate-rich protein is the gold standard for distinguishing reinfections from recrudescences in antimalarial drug trials. We compared performance of the recently developed 24-single-nucleotide polymorphism (SNP) Barcoding Assay against msp-1 and msp-2 genotyping in a cluster-randomized effectiveness trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in Malawi. Rates of recrudescence and reinfection estimated by the two methods did not differ significantly (Fisher's exact test; P = 0.887 and P = 0.768, respectively). There was a strong agreement between the two methods in predicting treatment outcomes and resolving the genetic complexity of malaria infections in this setting. These results support the use of this SNP assay as an alternative method for correcting antimalarial efficacy/effectiveness data.
- Published
- 2018
- Full Text
- View/download PDF